

Insulin Glargine and Lispro Market, Global Outlook and Forecast 2022-2028

https://marketpublishers.com/r/I8007DB77435EN.html

Date: January 2022

Pages: 76

Price: US\$ 3,250.00 (Single User License)

ID: I8007DB77435EN

Abstracts

As for March, 26 2020:

Dr. Eleanor Fish (a prominent immunologist at the University of Toronto, Canada) comments that she does not think BCG may completely eliminate infection caused by a novel coronavirus, but it is likely to mitigate the effects of a novel coronavirus on individuals. The scientists involved in the study hope that BCG vaccination may ease the burden on the health system before a specific vaccine for Covid-19 is available.

1.BCG Clinical Trials for Against Covid-19

Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods. They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether. The study will be administered to people at high risk, including physicians and nurses, and to older adults.

A team at the university of Melbourne in Australia is using exactly the same protocol to carry out the BCG study among healthcare workers. Another team at the university of Exeter in the UK will conduct a similar study on older people. Last week, a team at the Max Planck Institute for Infection Biology in Germany announced that, inspired by Netea's work, they would carry out similar clinical trials in older people and healthcare workers with another anti-tb vaccine in development, VPM1002, a genetically modified BCG vaccine. The elderly and health care workers are bearing the brunt of the current outbreak, so they would particularly benefit if the VPM1002 vaccine could help. They said.



2.Introduction of BCG

The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. The vaccine is in most countries in the world of children after the birth of the first annual vaccination is used, the BCG vaccine to be both safe and cheap, it can prevent an average of about 60% of TB cases, children vary widely between countries. Vaccines typically produce an immune response against the target pathogen, such as antibodies that bind and neutralize one virus but do not bind to others. But BCG may also enhance the immune system's ability to fight pathogens other than tuberculosis, according to decades of published clinical and observational studies. The researchers concluded that in the first year after vaccination, about 30 percent of all known pathogens, including viruses, could be prevented. A 2014 review by the world health organization concluded that BCG appeared to reduce overall child mortality.

3.BCG can 'Train' Innate Immunity

The innate immune system, composed of white blood cells such as macrophages, natural killer cells and neutrophils, should not have this memory. The team, led by professor Netea, found that BCG could survive for months in human skin, stimulating not only the t-cells and b-cells of mycobacterium memoriae, but also the white blood cells responsible for innate immunity, which can quickly respond to new infections. In a randomized placebo-controlled study published in 2018, the team showed that BCG vaccination prevented the yellow fever virus from being experimentally infected.

This report contains market size and forecasts of BCG Vaccine for Prevent Covid-19 in global, including the following market information:

Global BCG Vaccine for Prevent Covid-19 Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global BCG Vaccine for Prevent Covid-19 Market Sales, 2017-2022, 2023-2028, (K Doses)

Global top five BCG Vaccine for Prevent Covid-19 companies in 2021 (%)

The global BCG Vaccine for Prevent Covid-19 market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.



The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

by Dosage Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of BCG Vaccine for Prevent Covid-19 include Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, InterVax, Serum Institute of India, GreenSignal, Statens Serum Institute and Shanyao Group and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the BCG Vaccine for Prevent Covid-19 manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global BCG Vaccine for Prevent Covid-19 Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Doses)

Global BCG Vaccine for Prevent Covid-19 Market Segment Percentages, by Type, 2021 (%)

by Dosage

0.5ml Package

1ml Package

2ml Package

Other

by Type of Inoculator

Initial Vaccinate

Revaccination



Global BCG Vaccine for Prevent Covid-19 Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Doses)

Global BCG Vaccine for Prevent Covid-19 Market Segment Percentages, by Application, 2021 (%)

0-5 Years Old
5-18 Years Old
18-45 Years Old

?65 Years Old

45-65 Years Old

Global BCG Vaccine for Prevent Covid-19 Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Doses)

Global BCG Vaccine for Prevent Covid-19 Market Segment Percentages, By Region and Country, 2021 (%)

North America				
US				
Can	ada			
Mex	ico			
Europe				
Gerr	nany			

France



	U.K.			
	Italy			
	Russia			
	Nordic Countries			
	Benelux			
	Rest of Europe			
Asia				
	China			
	Japan			
	South Korea			
	Southeast Asia			
	India			
	Rest of Asia			
South America				
	Brazil			
	Argentina			
	Rest of South America			
Middle East & Africa				
	Turkey			
	Israel			



Saudi Arabia				
UAE				
Rest of Middle East & Africa				
Competitor Analysis				
The report also provides analysis of leading market participants including:				
Key companies BCG Vaccine for Prevent Covid-19 revenues in global market, 2017-2022 (Estimated), (\$ millions)				
Key companies BCG Vaccine for Prevent Covid-19 revenues share in global market, 2021 (%)				
Key companies BCG Vaccine for Prevent Covid-19 sales in global market, 2017-2022 (Estimated), (K Doses)				
Key companies BCG Vaccine for Prevent Covid-19 sales share in global market, 2021 (%)				
Further, the report presents profiles of competitors in the market, key players include:				
Merck				
Sanofi Pasteur				
Japan BCG Lab				
China National Biotec				
InterVax				
Serum Institute of India				
GreenSignal				



Statens Serum Institute

Shanyao Group

Shanghai Institute of Biological Products



Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Insulin Glargine and Lispro Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Insulin Glargine and Lispro Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL INSULIN GLARGINE AND LISPRO OVERALL MARKET SIZE

- 2.1 Global Insulin Glargine and Lispro Market Size: 2021 VS 2028
- 2.2 Global Insulin Glargine and Lispro Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Insulin Glargine and Lispro Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Insulin Glargine and Lispro Players in Global Market
- 3.2 Top Global Insulin Glargine and Lispro Companies Ranked by Revenue
- 3.3 Global Insulin Glargine and Lispro Revenue by Companies
- 3.4 Global Insulin Glargine and Lispro Sales by Companies
- 3.5 Global Insulin Glargine and Lispro Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Insulin Glargine and Lispro Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Insulin Glargine and Lispro Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Insulin Glargine and Lispro Players in Global Market
 - 3.8.1 List of Global Tier 1 Insulin Glargine and Lispro Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Insulin Glargine and Lispro Companies

4 SIGHTS BY PRODUCT

4.1 Overview



- 4.1.1 By Type Global Insulin Glargine and Lispro Market Size Markets, 2021 & 2028
- 4.1.2 Branded Drug
- 4.1.3 Biosimilar Drug
- 4.2 By Type Global Insulin Glargine and Lispro Revenue & Forecasts
- 4.2.1 By Type Global Insulin Glargine and Lispro Revenue, 2017-2022
- 4.2.2 By Type Global Insulin Glargine and Lispro Revenue, 2023-2028
- 4.2.3 By Type Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- 4.3 By Type Global Insulin Glargine and Lispro Sales & Forecasts
 - 4.3.1 By Type Global Insulin Glargine and Lispro Sales, 2017-2022
- 4.3.2 By Type Global Insulin Glargine and Lispro Sales, 2023-2028
- 4.3.3 By Type Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- 4.4 By Type Global Insulin Glargine and Lispro Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

- 5.1 Overview
 - 5.1.1 By Application Global Insulin Glargine and Lispro Market Size, 2021 & 2028
 - 5.1.2 Type I Dibetes
 - 5.1.3 Type II Dibetes
- 5.2 By Application Global Insulin Glargine and Lispro Revenue & Forecasts
 - 5.2.1 By Application Global Insulin Glargine and Lispro Revenue, 2017-2022
- 5.2.2 By Application Global Insulin Glargine and Lispro Revenue, 2023-2028
- 5.2.3 By Application Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- 5.3 By Application Global Insulin Glargine and Lispro Sales & Forecasts
 - 5.3.1 By Application Global Insulin Glargine and Lispro Sales, 2017-2022
 - 5.3.2 By Application Global Insulin Glargine and Lispro Sales, 2023-2028
- 5.3.3 By Application Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- 5.4 By Application Global Insulin Glargine and Lispro Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

- 6.1 By Region Global Insulin Glargine and Lispro Market Size, 2021 & 2028
- 6.2 By Region Global Insulin Glargine and Lispro Revenue & Forecasts
 - 6.2.1 By Region Global Insulin Glargine and Lispro Revenue, 2017-2022
 - 6.2.2 By Region Global Insulin Glargine and Lispro Revenue, 2023-2028



- 6.2.3 By Region Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- 6.3 By Region Global Insulin Glargine and Lispro Sales & Forecasts
 - 6.3.1 By Region Global Insulin Glargine and Lispro Sales, 2017-2022
 - 6.3.2 By Region Global Insulin Glargine and Lispro Sales, 2023-2028
- 6.3.3 By Region Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- 6.4 North America
 - 6.4.1 By Country North America Insulin Glargine and Lispro Revenue, 2017-2028
 - 6.4.2 By Country North America Insulin Glargine and Lispro Sales, 2017-2028
 - 6.4.3 US Insulin Glargine and Lispro Market Size, 2017-2028
 - 6.4.4 Canada Insulin Glargine and Lispro Market Size, 2017-2028
- 6.4.5 Mexico Insulin Glargine and Lispro Market Size, 2017-2028

6.5 Europe

- 6.5.1 By Country Europe Insulin Glargine and Lispro Revenue, 2017-2028
- 6.5.2 By Country Europe Insulin Glargine and Lispro Sales, 2017-2028
- 6.5.3 Germany Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.4 France Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.5 U.K. Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.6 Italy Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.7 Russia Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.8 Nordic Countries Insulin Glargine and Lispro Market Size, 2017-2028
- 6.5.9 Benelux Insulin Glargine and Lispro Market Size, 2017-2028

6.6 Asia

- 6.6.1 By Region Asia Insulin Glargine and Lispro Revenue, 2017-2028
- 6.6.2 By Region Asia Insulin Glargine and Lispro Sales, 2017-2028
- 6.6.3 China Insulin Glargine and Lispro Market Size, 2017-2028
- 6.6.4 Japan Insulin Glargine and Lispro Market Size, 2017-2028
- 6.6.5 South Korea Insulin Glargine and Lispro Market Size, 2017-2028
- 6.6.6 Southeast Asia Insulin Glargine and Lispro Market Size, 2017-2028
- 6.6.7 India Insulin Glargine and Lispro Market Size, 2017-2028

6.7 South America

- 6.7.1 By Country South America Insulin Glargine and Lispro Revenue, 2017-2028
- 6.7.2 By Country South America Insulin Glargine and Lispro Sales, 2017-2028
- 6.7.3 Brazil Insulin Glargine and Lispro Market Size, 2017-2028
- 6.7.4 Argentina Insulin Glargine and Lispro Market Size, 2017-2028

6.8 Middle East & Africa

- 6.8.1 By Country Middle East & Africa Insulin Glargine and Lispro Revenue, 2017-2028
 - 6.8.2 By Country Middle East & Africa Insulin Glargine and Lispro Sales, 2017-2028



- 6.8.3 Turkey Insulin Glargine and Lispro Market Size, 2017-2028
- 6.8.4 Israel Insulin Glargine and Lispro Market Size, 2017-2028
- 6.8.5 Saudi Arabia Insulin Glargine and Lispro Market Size, 2017-2028
- 6.8.6 UAE Insulin Glargine and Lispro Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

- 7.1 Sanofi S.A
 - 7.1.1 Sanofi S.A Corporate Summary
 - 7.1.2 Sanofi S.A Business Overview
 - 7.1.3 Sanofi S.A Insulin Glargine and Lispro Major Product Offerings
 - 7.1.4 Sanofi S.A Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.1.5 Sanofi S.A Key News
- 7.2 Eli Lilly and Company
 - 7.2.1 Eli Lilly and Company Corporate Summary
 - 7.2.2 Eli Lilly and Company Business Overview
 - 7.2.3 Eli Lilly and Company Insulin Glargine and Lispro Major Product Offerings
- 7.2.4 Eli Lilly and Company Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.2.5 Eli Lilly and Company Key News
- 7.3 Biocon Limited
 - 7.3.1 Biocon Limited Corporate Summary
 - 7.3.2 Biocon Limited Business Overview
 - 7.3.3 Biocon Limited Insulin Glargine and Lispro Major Product Offerings
- 7.3.4 Biocon Limited Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
- 7.3.5 Biocon Limited Key News
- 7.4 Cipla Limited
 - 7.4.1 Cipla Limited Corporate Summary
 - 7.4.2 Cipla Limited Business Overview
 - 7.4.3 Cipla Limited Insulin Glargine and Lispro Major Product Offerings
- 7.4.4 Cipla Limited Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
- 7.4.5 Cipla Limited Key News
- 7.5 Gan & Lee Pharmaceutical Ltd.
 - 7.5.1 Gan & Lee Pharmaceutical Ltd. Corporate Summary
 - 7.5.2 Gan & Lee Pharmaceutical Ltd. Business Overview
- 7.5.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Major Product Offerings



- 7.5.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.5.5 Gan & Lee Pharmaceutical Ltd. Key News
- 7.6 Julphar Diabetes LLC
 - 7.6.1 Julphar Diabetes LLC Corporate Summary
 - 7.6.2 Julphar Diabetes LLC Business Overview
- 7.6.3 Julphar Diabetes LLC Insulin Glargine and Lispro Major Product Offerings
- 7.6.4 Julphar Diabetes LLC Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
- 7.6.5 Julphar Diabetes LLC Key News
- 7.7 Merck & Co.
 - 7.7.1 Merck & Co. Corporate Summary
 - 7.7.2 Merck & Co. Business Overview
 - 7.7.3 Merck & Co. Insulin Glargine and Lispro Major Product Offerings
- 7.7.4 Merck & Co. Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
- 7.7.5 Merck & Co. Key News
- 7.8 Novo Nordisk A/S
 - 7.8.1 Novo Nordisk A/S Corporate Summary
 - 7.8.2 Novo Nordisk A/S Business Overview
 - 7.8.3 Novo Nordisk A/S Insulin Glargine and Lispro Major Product Offerings
- 7.8.4 Novo Nordisk A/S Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.8.5 Novo Nordisk A/S Key News
- 7.9 SAJA Pharmaceuticals
 - 7.9.1 SAJA Pharmaceuticals Corporate Summary
 - 7.9.2 SAJA Pharmaceuticals Business Overview
 - 7.9.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Major Product Offerings
- 7.9.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.9.5 SAJA Pharmaceuticals Key News
- 7.10 Wockhardt Ltd.
 - 7.10.1 Wockhardt Ltd. Corporate Summary
 - 7.10.2 Wockhardt Ltd. Business Overview
- 7.10.3 Wockhardt Ltd. Insulin Glargine and Lispro Major Product Offerings
- 7.10.4 Wockhardt Ltd. Insulin Glargine and Lispro Sales and Revenue in Global (2017-2022)
 - 7.10.5 Wockhardt Ltd. Key News



8 GLOBAL INSULIN GLARGINE AND LISPRO PRODUCTION CAPACITY, ANALYSIS

- 8.1 Global Insulin Glargine and Lispro Production Capacity, 2017-2028
- 8.2 Insulin Glargine and Lispro Production Capacity of Key Manufacturers in Global Market
- 8.3 Global Insulin Glargine and Lispro Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

- 9.1 Market Opportunities & Trends
- 9.2 Market Drivers
- 9.3 Market Restraints

10 INSULIN GLARGINE AND LISPRO SUPPLY CHAIN ANALYSIS

- 10.1 Insulin Glargine and Lispro Industry Value Chain
- 10.2 Insulin Glargine and Lispro Upstream Market
- 10.3 Insulin Glargine and Lispro Downstream and Clients
- 10.4 Marketing Channels Analysis
 - 10.4.1 Marketing Channels
- 10.4.2 Insulin Glargine and Lispro Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

- 12.1 Note
- 12.2 Examples of Clients
- 12.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Key Players of Insulin Glargine and Lispro in Global Market
- Table 2. Top Insulin Glargine and Lispro Players in Global Market, Ranking by Revenue (2021)
- Table 3. Global Insulin Glargine and Lispro Revenue by Companies, (US\$, Mn), 2017-2022
- Table 4. Global Insulin Glargine and Lispro Revenue Share by Companies, 2017-2022
- Table 5. Global Insulin Glargine and Lispro Sales by Companies, (Liter), 2017-2022
- Table 6. Global Insulin Glargine and Lispro Sales Share by Companies, 2017-2022
- Table 7. Key Manufacturers Insulin Glargine and Lispro Price (2017-2022) & (USD/mL)
- Table 8. Global Manufacturers Insulin Glargine and Lispro Product Type
- Table 9. List of Global Tier 1 Insulin Glargine and Lispro Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Insulin Glargine and Lispro Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type Global Insulin Glargine and Lispro Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2017-2022
- Table 13. By Type Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2023-2028
- Table 14. By Type Global Insulin Glargine and Lispro Sales (Liter), 2017-2022
- Table 15. By Type Global Insulin Glargine and Lispro Sales (Liter), 2023-2028
- Table 16. By Application Global Insulin Glargine and Lispro Revenue, (US\$, Mn), 2021 & 2028
- Table 17. By Application Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2017-2022
- Table 18. By Application Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2023-2028
- Table 19. By Application Global Insulin Glargine and Lispro Sales (Liter), 2017-2022
- Table 20. By Application Global Insulin Glargine and Lispro Sales (Liter), 2023-2028
- Table 21. By Region Global Insulin Glargine and Lispro Revenue, (US\$, Mn), 2021 VS 2028
- Table 22. By Region Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2017-2022
- Table 23. By Region Global Insulin Glargine and Lispro Revenue (US\$, Mn), 2023-2028
- Table 24. By Region Global Insulin Glargine and Lispro Sales (Liter), 2017-2022



Table 25. By Region - Global Insulin Glargine and Lispro Sales (Liter), 2023-2028

Table 26. By Country - North America Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Insulin Glargine and Lispro Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Insulin Glargine and Lispro Sales, (Liter), 2017-2022

Table 29. By Country - North America Insulin Glargine and Lispro Sales, (Liter), 2023-2028

Table 30. By Country - Europe Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Insulin Glargine and Lispro Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Insulin Glargine and Lispro Sales, (Liter), 2017-2022

Table 33. By Country - Europe Insulin Glargine and Lispro Sales, (Liter), 2023-2028

Table 34. By Region - Asia Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Insulin Glargine and Lispro Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Insulin Glargine and Lispro Sales, (Liter), 2017-2022

Table 37. By Region - Asia Insulin Glargine and Lispro Sales, (Liter), 2023-2028

Table 38. By Country - South America Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Insulin Glargine and Lispro Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Insulin Glargine and Lispro Sales, (Liter), 2017-2022

Table 41. By Country - South America Insulin Glargine and Lispro Sales, (Liter), 2023-2028

Table 42. By Country - Middle East & Africa Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Insulin Glargine and Lispro Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Insulin Glargine and Lispro Sales, (Liter), 2017-2022

Table 45. By Country - Middle East & Africa Insulin Glargine and Lispro Sales, (Liter), 2023-2028

Table 46. Sanofi S.A Corporate Summary

Table 47. Sanofi S.A Insulin Glargine and Lispro Product Offerings

Table 48. Sanofi S.A Insulin Glargine and Lispro Sales (Liter), Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)



- Table 49. Eli Lilly and Company Corporate Summary
- Table 50. Eli Lilly and Company Insulin Glargine and Lispro Product Offerings
- Table 51. Eli Lilly and Company Insulin Glargine and Lispro Sales (Liter), Revenue

(US\$, Mn) and Average Price (USD/mL) (2017-2022)

- Table 52. Biocon Limited Corporate Summary
- Table 53. Biocon Limited Insulin Glargine and Lispro Product Offerings
- Table 54. Biocon Limited Insulin Glargine and Lispro Sales (Liter), Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)
- Table 55. Cipla Limited Corporate Summary
- Table 56. Cipla Limited Insulin Glargine and Lispro Product Offerings
- Table 57. Cipla Limited Insulin Glargine and Lispro Sales (Liter), Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)
- Table 58. Gan & Lee Pharmaceutical Ltd. Corporate Summary
- Table 59. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Offerings
- Table 60. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales (Liter),

Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)

- Table 61. Julphar Diabetes LLC Corporate Summary
- Table 62. Julphar Diabetes LLC Insulin Glargine and Lispro Product Offerings
- Table 63. Julphar Diabetes LLC Insulin Glargine and Lispro Sales (Liter), Revenue

(US\$, Mn) and Average Price (USD/mL) (2017-2022)

- Table 64. Merck & Co. Corporate Summary
- Table 65. Merck & Co. Insulin Glargine and Lispro Product Offerings
- Table 66. Merck & Co. Insulin Glargine and Lispro Sales (Liter), Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)
- Table 67. Novo Nordisk A/S Corporate Summary
- Table 68. Novo Nordisk A/S Insulin Glargine and Lispro Product Offerings
- Table 69. Novo Nordisk A/S Insulin Glargine and Lispro Sales (Liter), Revenue (US\$,

Mn) and Average Price (USD/mL) (2017-2022)

- Table 70. SAJA Pharmaceuticals Corporate Summary
- Table 71. SAJA Pharmaceuticals Insulin Glargine and Lispro Product Offerings
- Table 72. SAJA Pharmaceuticals Insulin Glargine and Lispro Sales (Liter), Revenue

(US\$, Mn) and Average Price (USD/mL) (2017-2022)

- Table 73. Wockhardt Ltd. Corporate Summary
- Table 74. Wockhardt Ltd. Insulin Glargine and Lispro Product Offerings
- Table 75. Wockhardt Ltd. Insulin Glargine and Lispro Sales (Liter), Revenue (US\$, Mn) and Average Price (USD/mL) (2017-2022)
- Table 76. Insulin Glargine and Lispro Production Capacity (Liter) of Key Manufacturers in Global Market, 2020-2022 (Liter)
- Table 77. Global Insulin Glargine and Lispro Capacity Market Share of Key



Manufacturers, 2020-2022

- Table 78. Global Insulin Glargine and Lispro Production by Region, 2017-2022 (Liter)
- Table 79. Global Insulin Glargine and Lispro Production by Region, 2023-2028 (Liter)
- Table 80. Insulin Glargine and Lispro Market Opportunities & Trends in Global Market
- Table 81. Insulin Glargine and Lispro Market Drivers in Global Market
- Table 82. Insulin Glargine and Lispro Market Restraints in Global Market
- Table 83. Insulin Glargine and Lispro Raw Materials
- Table 84. Insulin Glargine and Lispro Raw Materials Suppliers in Global Market
- Table 85. Typical Insulin Glargine and Lispro Downstream
- Table 86. Insulin Glargine and Lispro Downstream Clients in Global Market
- Table 87. Insulin Glargine and Lispro Distributors and Sales Agents in Global Market



List Of Figures

LIST OF FIGURES

- Figure 1. Insulin Glargine and Lispro Segment by Type
- Figure 2. Insulin Glargine and Lispro Segment by Application
- Figure 3. Global Insulin Glargine and Lispro Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Insulin Glargine and Lispro Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Insulin Glargine and Lispro Revenue, 2017-2028 (US\$, Mn)
- Figure 7. Insulin Glargine and Lispro Sales in Global Market: 2017-2028 (Liter)
- Figure 8. The Top 3 and 5 Players Market Share by Insulin Glargine and Lispro Revenue in 2021
- Figure 9. By Type Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 10. By Type Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 11. By Type Global Insulin Glargine and Lispro Price (USD/mL), 2017-2028
- Figure 12. By Application Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 13. By Application Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 14. By Application Global Insulin Glargine and Lispro Price (USD/mL), 2017-2028
- Figure 15. By Region Global Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 16. By Region Global Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 17. By Country North America Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 18. By Country North America Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 19. US Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 20. Canada Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 21. Mexico Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 22. By Country Europe Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 23. By Country Europe Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 24. Germany Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028



- Figure 25. France Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 26. U.K. Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 27. Italy Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 28. Russia Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 29. Nordic Countries Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 30. Benelux Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 31. By Region Asia Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 32. By Region Asia Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 33. China Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 34. Japan Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 35. South Korea Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 36. Southeast Asia Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 37. India Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 38. By Country South America Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 39. By Country South America Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 40. Brazil Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 41. Argentina Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 42. By Country Middle East & Africa Insulin Glargine and Lispro Revenue Market Share, 2017-2028
- Figure 43. By Country Middle East & Africa Insulin Glargine and Lispro Sales Market Share, 2017-2028
- Figure 44. Turkey Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 45. Israel Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 46. Saudi Arabia Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 47. UAE Insulin Glargine and Lispro Revenue, (US\$, Mn), 2017-2028
- Figure 48. Global Insulin Glargine and Lispro Production Capacity (Liter), 2017-2028
- Figure 49. The Percentage of Production Insulin Glargine and Lispro by Region, 2021 VS 2028
- Figure 50. Insulin Glargine and Lispro Industry Value Chain
- Figure 51. Marketing Channels



I would like to order

Product name: Insulin Glargine and Lispro Market, Global Outlook and Forecast 2022-2028

Product link: https://marketpublishers.com/r/l8007DB77435EN.html

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l8007DB77435EN.html